Professor David Fairlie is internationally known for his research contributions in the fields of medicinal chemistry, organic chemistry, biological chemistry and in several disciplines in biology (pharmacology, virology, immunology, neurobiology, biochemistry). He has had strong research programs in chemistry, biochemistry and pharmacology continuously funded by the Australian Research Council (ARC) since 1991 and the National Health and Medical Research Council (NHMRC) since 1995. He was awarded prestigious fellowships from the ARC, in the form of an Australian Professorial Fellowship (2002-2006) and an Australian Federation Fellowship (2006-2011), and from the NHMRC, in the form of a Senior Principal Research Fellowship (2012-2016 and 2017-2021). He has held numerous research grants in chemistry, biochemistry, pharmacology, virology, immunology, parasitology, neurobiology and oncology; including 15 multimillion dollar grants from industry and governments. He has served on academic and industry advisory panels, company boards, and research grant panels both in Australia and overseas. He collaborates with some of the world's largest pharmaceutical companies.

Professor Fairlie has >300 publications (h index >60; >14,000 citations; >35 cites per article; >30 articles >100 citations) and presents 5-10 invited plenary and keynote lectures around the world each year. He is also well known in the international pharmaceutical arena, having consulted to multiple big pharma on protease inhibitors, GPCR modulators, protein and peptide mimics, drug design and discovery, and pharmacology. He has been involved in four startup companies in Australia and the USA.


ResearcherID Scopus Orcid

Researcher biography

Professor Fairlie was appointed as Head of IMB's Chemistry and Structural Biology Division in 2009. He is one of a team of ten IMB group leaders and four division affiliates working across the disciplines of chemistry, biochemistry and pharmacology.

Professor Fairlie completed his undergraduate studies at The University of Adelaide, postgraduate studies at Australian National University and The University of New South Wales, and postdoctoral studies at Stanford University and The University of Toronto. He has held Australian Research Council(ARC) Federation and Professorial fellowships and chief scientific officer and scientific director roles in leading scientific companies. He has also collaborated with some of the world's largest biopharmaceutical companies.

Professor Fairlie is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow.

Featured projects Duration
Chemistry and human therapeutics